Investigating new treatments for high-risk localized prostate cancer
Official title: Efficacy and Mechanisms of Resistance to Neoadjuvant Intensive Androgen Signaling Inhibition
Funded at Dana-Farber Cancer Inst · NIH-10916197 · Data updated 2026-11-12
This study is looking at a new way to help men with high-risk prostate cancer by using stronger hormone therapy before surgery to see if it can lead to better treatment results and longer survival.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $443,790 |
| NIH project number | 5P50CA272390-02 |
| Project ID | NIH-10916197 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with localized high-risk prostate cancer who are planning to undergo radical prostatectomy.
✕Less likely to help
Patients with low-risk prostate cancer or those who have already undergone treatment may not benefit from this research.
What this research studies
This research focuses on improving treatment outcomes for patients with localized high-risk prostate cancer, which often has a low cure rate after surgery. The approach involves using a more intensive form of androgen signaling inhibition therapy before surgery, combining medications like leuprolide with abiraterone or enzalutamide. By examining the effectiveness of this neoadjuvant therapy, the research aims to increase the rates of complete pathological responses and improve long-term survival for patients. Participants will be monitored for their response to treatment and the underlying mechanisms of any resistance encountered.
Why it matters
Potential benefit: If successful, this research could lead to higher cure rates and better long-term outcomes for patients with high-risk localized prostate cancer.
How similar studies have gone: Previous studies have shown limited success with standard neoadjuvant therapies, making this approach novel and potentially groundbreaking.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Taplin, Mary Ellen — Dana-Farber Cancer Inst
- Study coordinator: Taplin, Mary Ellen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.